CASE STUDY

Spinal Muscular Atrophy after Nusinersen Therapy

Spinal Muscular Atrophy after Nusinersen Therapy: Improved Physiology in Pediatric Patients with No Significant Change in Urine, Serum, and Liquor 1H-NMR Metabolomes in Comparison to an Age-Matched, Healthy Cohort

The 5q spinal muscular atrophy (SMA) is a rare neuromuscular disorder, which leads to progressive atrophy and weakening of skeletal muscles due to the progressive loss of motor neurons. It is characterized by degeneration of the motor neurons in the anterior horn of the spinal cord, resulting in atrophy and weakness of the voluntary muscles of the limbs and trunk. With the incidence of about one in 11,000 live births, it was, until the development of disease-modifying drugs, the most common genetic cause of child deaths. The gene for the survival motor neuron (SMN) was localized in 1990 by two different groups on chromosome 5q13 and in 1996 was identified as the disease-causing gene.

Leon Deutsch, Biotechnical Faculty, University of Ljubljana, Jamnikarjeva, Slovenia,
Damjan Osredkar, Department of Pediatric Neurology, University Children’s Hospital, University Medical Centre Ljubljana, SI-1000 Ljubljana, Slovenia,
Janez Plavec, National Institute of Chemistry, NMR Center, SI-1000 Ljubljana, Slovenia,
Blaz Stres, Faculty of Civil and Geodetic Engineering, University of Ljubljana, Jamova, Slovenia & Department of Microbiology, University of Innsbruck, Austria

www.mdpi.com/2218-1989/11/4/206

Abstract

Spinal muscular atrophy (SMA) is a genetically heterogeneous group of rare neuromuscular diseases and was until recently the most common genetic cause of death in children. The effects of 2-month nusinersen therapy on urine, serum, and liquor 1H-NMR metabolomes in SMA males and females were not explored yet, especially not in comparison to the urine 1H-NMR metabolomes of matching male and female cohorts. In this prospective, single-centered study, urine, serum, and liquor samples were collected from 25 male and female pediatric patients with SMA before and after 2 months of nusinersen therapy and urine samples from a matching healthy cohort (n = 125). Nusinersen intrathecal application was the first therapy for the treatment of SMA by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Metabolomes were analyzed using targeted metabolomics utilizing 600 MHz 1H-NMR, parametric and nonparametric multivariate statistical analyses, machine learning, and modeling. Medical assessment before and after nusinersen therapy showed significant improvements of movement, posture, and strength according to various medical tests. No significant differences were found in metabolomes before and after nusinersen therapy in urine, serum, and liquor samples using an ensemble of statistical and machine learning approaches. In comparison to a healthy cohort, 1H-NMR metabolomes of SMA patients contained a reduced number and concentration of urine metabolites and differed significantly between males and females as well. Significantly larger data scatter was observed for SMA patients in comparison to matched healthy controls. Machine learning confirmed urinary creatinine as the most significant, distinguishing SMA patients from the healthy cohort. The positive effects of nusinersen therapy clearly preceded or took place devoid of significant rearrangements in the 1H-NMR metabolomic makeup of serum, urine, and liquor. Urine creatinine was successful at distinguishing SMA patients from the matched healthy cohort, which is a simple systemic novelty linking creatinine and SMA to the physiology of inactivity and diabetes, and it facilitates the monitoring of SMA disease in pediatric patients through non-invasive urine collection.

Read more: Spinal Muscular Atrophy after Nusinersen Therapy: Improved Physiology in Pediatric Patients with No Significant Change in Urine, Serum, and Liquor 1H-NMR Metabolomes in Comparison to an Age-Matched, Healthy Cohort

How was AutoML used?

JADBio, a web-based auto machine learning platform for analyzing potential biomarkers, was used. The JADBIO platform was designed for predictive modeling and to provide high-quality predictive models for diagnostics using state-of-the-art statistical and machine learning methods. Personal analytic biases and methodological statistical errors were eliminated from the analysis by the autonomous exploration of various settings in modeling steps producing more convincing discovered features to discriminate between SMA and the healthy group. JADBIO 1.1.164 with extensive tuning effort and 6 CPU was used to model various dataset selections next to the overall 336 metabolites observed in urine samples in all groups (healthy versus SMA group) by splitting the total urine metabolite data into a training set and a test set in a 70:30 ratio. The training set was used for model training and the test set was used for model evaluation.
The resulting model can be obtained as part of Supplementary Material (ESM2) and run with java executor for the classification of novel urine samples based on 1H-NMR metabolomes in further exploration.

Keywords: #spinalmuscularatrophy #SMA #atrophy

OTHER

CASE STUDIES

Do you have questions?

JADBio can meet your needs. Ask one of our experts for an interactive demo.

Stay connected to get our news first!

Do you have questions?

JADBio can meet your needs. Ask one of our experts for an interactive demo.

JADai by JADBio
REQUEST A DEMO

Join the JADai Community!

Sign up with a FREE Basic plan! Be part of a growing community of AutoML enthusiasts

JADBio JADai